The Study

Determine immunity in Germany

Cross-sectional SARS-CoV-2 serosurvey


The aim of this study is to determine more reliably the prevalence of infections with SARS-CoV-2 and the corresponding immunity in different population groups in Germany. From these data as well as data from further studies, measures can be evaluated. Thus, a contribution can be made to strive for normalization within a reasonable framework.
The main goal of this study is to determine the proportion of the population that has SARS-CoV-2 antibodies. This will be done for each study site, also in comparison to other study sites. In addition, different age groups and self-reported symptoms of SARS-CoV-2 infection will be analyzed.
Another part of this study is the observation of incidence over a year, as well as multiple determinations of antibody concentration in the blood of actual positive reported COVID-19 patients. Thereby we hope to gain insights into how long a person is immune to the virus.
People in eight counties throughout Germany will be tested, and up to 60,000 aged 18 and older can participate in the study. After 3-4 months, the antibodies of the people in the participating counties will be tested again in order to be able to observe the spread, also with regard to any relaxation measures taken, as well as to document the progress of the “contamination” of the population.
The nationwide antibody study is funded by the Helmholtz Association of German Research Centers.

IParticipant information (version 1.3)

MuSPAD Logo blue